Pharmaceutical Executive-02-01-2018

Pharmaceutical Executive

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders-most importantly, patients and the wider public.

Pharmaceutical Executive

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

Pharmaceutical Executive

The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.

Pharmaceutical Executive
Features

February 11, 2018

Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.

Pharmaceutical Executive

Low-cost follow-ons and biosimilars please payers but heighten competitive battles with brands.

Pharmaceutical Executive
Columns

February 06, 2018

Assembling a few rare slivers of pharma positivity on UK’s future.

Pharmaceutical Executive
From the Editor

February 06, 2018

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders-call it the quest to see "what right looks like?"

Pharmaceutical Executive
Features

February 02, 2018

2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead?

Pharmaceutical Executive
Special Sponsored Section

February 01, 2018

In its ambition to further strengthen the nation’s relationship with the global industry, Brazil holds a valuable, eye-catching asset: the dynamism of its huge pharmaceutical market, the sixth-largest in the world.

Issue PDF
Pharmaceutical Executive

February 01, 2018

Click the title above to open the Pharmaceutical Executive February 2018 issue in an interactive PDF format.